WTZ Cancer Center Director Univ. Prof. Dr. med. Angelika Eggert ...

2. Coordinator: Max E. Scheulen, MD, PhD
Prof. Dr. med. Dipl.-Biochem. Max E. Scheulen
Clinical Phase I-Unit and Pharmacology of
Antineoplastic Substances
6. Selected publications 2002 – 2008
Kruijtzer, C. M. F., Schellens, J. H. M., Mezger, J., Scheulen, M. E., Keilholz, U., Beijnen, J. H.,
Rosing, H., Mathôt, R. A. A., Marcus, S., van Tinteren, H., Baas, P.: A phase II and pharmacologic
study of weekly oral paclitaxel plus cyclosporin A in patients with advanced
non-small cell lung cancer.
J. Clin. Oncol. 20, 4508-4516 (2002) IF 9,8
Mross K, Richly H, Schleucher N, Korfee S, Tewes M, Scheulen ME, Seeber S, Beinert T,
Schweigert M, Sauer U, Unger C, Behringer D, Brendel E, Haase CG, Voliotis D, Strumberg D.
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441,
as a daily infusion in patients with advanced solid tumors.
Ann Oncol. (2004) 15:1284-94. IF 4,3
Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, Foerster MH,
Thiel E, Keilholz U. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with
metastatic uveal melanoma.
Melanoma Res. (2005) 15:205-7. IF 2,1
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M.,
Brendel, E., Voliotis, D., Haase, C. G., Schwartz, B., Awada, A., Voigtmann, R., Scheulen,
M. E., Seeber, S.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and
vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced
refractory solid tumors.
J. Clin. Oncol. 23, 965-972 (2005) IF 9,8
Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B,
Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy
worsening.
Neurology. (2005) 64: 1076-7. IF 5,7
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W.,
Hess, D., Morant, R., Semiglazov, V., Borner, M., Salzberg, M., Ostapenko, V., Illiger, H. J.,
Behringer, D., Bardy-Bouxin, N., Boni, J., Kong, S., Cincotta, M., Moore, L.: Phase 2 study of
temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally
advanced or metastatic breast cancer.
J. Clin. Oncol. 23, 5314-5322 (2005). IF 9,8
Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O.,
Brendel, E., Schwartz, B., Ludwig, M., Flashar, C., Voigtmann, R., Scheulen, M. E., Seeber, S.,
Strumberg, D.: Results of a phase I trial of sorafenib (BAY 43-9006) in combination with
doxorubicin in patients with refractory solid tumors.
Ann. Oncol. 17, 866-873 (2006). IF 4,3
Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S,
Scheulen ME. Risk factors for venous thromboembolic events in cancer patients.
Ann Oncol. (2006) 17:297-303. IF 4,3
Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, Opalka B, Seeber S,
Flasshove M, Moritz T.: ene transfer of cytidine deaminase protects myelopoiesis from cytidine
analogs in an in vivo murine transplant model.
Blood 108, :2965-2971 (2006). IF 10.1
Steinbild, S., Mross, K., Frost, A., Morant, R., Gillessen, S., Dittrich, C., Strumberg, D., Hochhaus,
A., Hanauske, A., Edler, L., Burkholder, I., Scheulen, M. E.: A clinical phase II study with sorafenib
in patients with hormone-refractory prostate cancer – a study of the CESAR Central European
Society for Anticancer Drug Research-EWIV.
Brit. J. Cancer 97:1480-1485 (2007). IF 4.1